Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026

Nature of Filing / Announcement: Financial Results under Regulation 33 of SEBI LODR

Date of Board Meeting / Approval: November 14, 2026 (10:30 AM IST to 11:45 AM IST)

Audit Opinion: Unmodified review report (clean opinion)

Auditor's Comment: Nothing came to their attention causing belief that the statement contains material misstatement

Key Financial Highlights [Rs. in Lakhs]

Standalone Results (Continuing Operations):

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹1.10 lakhs (vs ₹1.45 lakhs in Q1 FY27)
  • Total Income: ₹1,703.52 lakhs
  • Net Profit/(Loss): ₹578.45 lakhs profit
  • EPS: ₹0.30 (Basic and Diluted)

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹2.55 lakhs
  • Total Income: ₹2,332.99 lakhs
  • Net Profit/(Loss): ₹(1,138.15) lakhs loss
  • EPS: ₹(0.59) (Basic and Diluted)

Financial Position (Standalone as at September 30, 2026):

  • Cash and Cash Equivalents: ₹11,224.77 lakhs
  • Other Equity: ₹55,469.15 lakhs
  • Debt: Not Specified (no borrowings shown in current/non-current liabilities)
  • Total Assets: ₹59,662.61 lakhs

Consolidated Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹1.10 lakhs
  • Total Income: ₹1,406.81 lakhs
  • Net Profit/(Loss): ₹356.36 lakhs profit

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹2.55 lakhs
  • Total Income: ₹1,743.01 lakhs
  • Net Profit/(Loss): ₹(1,734.76) lakhs loss

Financial Position (Consolidated as at September 30, 2026):

  • Cash and Cash Equivalents: ₹11,554.86 lakhs
  • Other Equity: ₹55,019.53 lakhs
  • Total Assets: ₹60,133.19 lakhs

Segment-wise Performance:

The Company is exclusively in the pharmaceutical business segment.

Discontinued Operations (Capsule Business and Jammu Unit):

Half Year Ended September 30, 2026:

  • Revenue from operations: ₹735.17 lakhs
  • Total expenses: ₹821.96 lakhs
  • Net loss after tax: ₹(51.86) lakhs

Year Ended March 31, 2026 (Audited):

  • Revenue from operations: ₹40,138.43 lakhs
  • Exceptional item (Gain on slump sale): ₹16,337.32 lakhs
  • Net loss after tax: ₹(23,554.38) lakhs

Corporate Actions:

Not Specified

Other Significant Information:

Going Concern:

The Company sold a substantial part of its existing business operations by way of slump sale in the previous financial year and incurred losses. The transaction resulted in significant liquidity, and after discharging all its debts, the Company possesses adequate cash and liquid resources. The Company amended its object clause to undertake activities in the real estate sector and is evaluating various projects under the revised business framework. The Board believes the Company will continue as a going concern.

Material Transactions:

Assets Classified as Held for Sale:

1. Capsule Business (EHGC): Entered into Business Transfer Agreement with Capnest Health Care Private Limited dated December 20, 2025, for slump sale of Empty Hard Gelatin Capsule business for consideration of ₹1,990.00 lakhs

2. Jammu Unit: Fixed assets pertaining to the inoperative Jammu unit disposed of during the period

3. Other Assets: Evaluating monetization of land near Garhshankar, Punjab (portion already sold in current quarter)

Investment Losses:

The Company deployed surplus funds in mutual funds, ETFs, and equity instruments. Market volatility and geopolitical developments adversely impacted the value of investments, resulting in a loss of ₹2,672.50 lakhs for the half year ended September 30, 2026 (includes loss of ₹2,513.29 lakhs up to June 30, 2026).